Praxis Faces Earnings Miss and Stock Drop Following Trial Challenges Praxis Precision Medicines reported a quarterly loss of $2.94 per share, missing estimates. The company’s stock opened significantly lower, reflecting investor concerns over halted clinical trials. Despite financial setbacks, Praxis continues to advance its epilepsy treatments, with key results anticipated later this year, aiming to regain market confidence.456